Author Archives: Bruno Quinney

#GLP-1 #Mounjaro #Obesity #Ozempic #Weight loss

Weight-loss drugs’ challenge to pharma’s safety infrastructure

For the huge commercial success represented by GLP-1 agonists such as Mounjaro and Ozempic, particularly now in the context of treating obesity, they also present an operational nightmare for companies. That's as  volumes of adverse events threaten to swamp existing safety workflows. Qinecsa’s Daniel O’Keeffe assesses the scale of the problem.  The success of Glucagon-Like Peptide-1 (GLP-1) receptor agonists as modern weight-loss solutions has yet to… Read More

#Exclusive Content #Opinion

Non-small cell lung cancer
#Lung cancer #National Institute for Health and Care Excellence (NICE) #NHS #Non-small cell lung cancer (NSCLC) #Regeneron Pharmaceuticals

NICE recommends lung cancer combination therapy 

The National Institute for Health and Care Excellence (NICE) has recommended cemiplimab in combination with platinum-based chemotherapy to treat patients with non-small cell lung cancer (NSCLC).  Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, which was shown to block cancer cells from using the PD-1… Read More

#News #Regulatory

Delegates at a conference
#Lab automation #Purification technology #SLAS2026

SLAS reveals New Product Awards winners 

SLAS has revealed the winners of its New Product Awards, drawing the Vienna conference to a close.  Among the winners are Bionomous for its Sortivo technology, a next-generation large-particle sorter, Cube Biotech with its PlateX MP Strep-TactinXT MagBeads product, which enables automated membrane protein purification from lysate to analytical-grade samples, and nNano AG for the CERTUS RIVO, a dispensing… Read More

#News

Soft tissue sarcoma
#Clinical trial #RNA modifying enzymes #Sarcoma

Enzyme inhibitor shows early evidence of treating sarcoma 

An RNA-modifying enzyme inhibitor has shown positive results in treating sarcoma patients during a Phase I trial.  STC-15, developed by STORM Therapeutics, demonstrated a disease control rate of 54% at 12 weeks and a median progression-free survival of six months. The trial enrolled 42 patients with advanced… Read More

#Cancer Research #News

#Cancer research #Drug discovery #Opioids

Repurposing EGFR inhibitors to target cancer pain and opioid tolerance

Dr Yi Ye and Dr Vanessa Uzonwan examine research that suggests how cancer drugs may be repurposed to manage oral cancer pain.  Cancer-associated pain remains a major clinical challenge, particularly in oral squamous cell carcinoma (OSCC), where patients experience severe pain during eating and speaking alongside substantial declines in quality of life. Despite advances in… Read More

#Exclusive Content

Cholesterol test
#Cardiovascular disease #Cholesterol #Eli Lilly #Gene therapy

Single-shot gene therapy could cut cholesterol by 62% 

A single-shot gene therapy could slash cholesterol levels by 62%, potentially ‘transforming cardiovascular care’.  Results from the Heart-2 study into VERVE-102, published in The New England Journal of Medicine, showed reductions of up to 62% in a cohort of 35 participants, with durability observed for up… Read More

#News

#AstraZeneca #Drug discovery #Europe #European Federation of Pharmaceutical Industries and Associations #FDA #Francis Crick Institute #Hypertension #Lung cancer #Mental health #Tropical disease #University of Dundee #Wellcome Trust

DDW Highlights: 26 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a report showed patients in Europe face barriers to medicine access. Elsewhere,… Read More

#Podcasts

Myeloma
#HaemaLogiX #Myeloma #Phase I trial

HaemaLogiX launches Phase I multiple myeloma trial 

Biotechnology company HaemaLogiX has begun patient enrolment for a Phase I study evaluating a therapy for multiple myeloma.  The KOALA study is a Phase I dose‑escalation trial assessing the safety and preliminary efficacy of KMCAR T‑cell, a novel autologous CAR‑T therapy targeting the Kappa Myeloma Antigen (KMA), a tumour‑specific receptor… Read More

#News

Researcher pipetting samples in microplate
#ASGCT #DNA #Genetic medicines

Company shows ‘new therapeutic modality’ at ASGCT 2026 

Serif Biomedicines has announced preclinical data showing the potential of its Modified DNA as a new class of genetic medicines.  Results from non-human primates, announced at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2026, suggest Modified DNA could overcome barriers of innate immune… Read More

#News

#Cancer research #Gut microbiome #Immuno-oncology #Melanoma #Non-small cell lung cancer (NSCLC)

Improving response: Microbiome-based approaches to checkpoint inhibitor resistance

Sheri Simmons, Acting Chief Scientific Officer at MaaT Pharma, explores how a diversified gut microbiome could improve the treatment of cancer.   Harnessing the microbiome is emerging as a promising strategy to enhance the body’s response to certain anti-cancer therapies and to mitigate treatment-related toxicities (1). Clinical evidence indicates that gut microbiome composition contributes to patient… Read More

#Cancer Research #Exclusive Content

Laboratory research
#Advanced Therapies #Clinical trial #UK

UK introduces framework for advanced therapy trials 

The UK is set to introduce a national framework to boost advanced therapy clinical trials.  The Advanced Therapy Clinical Trials Capability Framework, produced jointly by the Advanced Therapy Treatment Centre (ATTC) network, the Cell and Gene Therapy Catapult and Skills for Health, provides a shared strategic resource… Read More

#News

Europe
#Europe #European Federation of Pharmaceutical Industries and Associations #FDA

Patients in Europe face barriers to medicine access 

Patients in Europe are waiting longer to access medicines than patients in the US, a new report warns.  The European Federation of Pharmaceutical Industries and Associations (EFPIA)’s report shows 49% of FDA-approved medicines are not available in Europe, up from 46% in 2019.  Data also indicates 17% of medicines are… Read More

#Editor's Choice #News #Regulatory

#Cancer research #Medicines Discovery Catapult #Nuclear medicine #Radiopharmaceuticals #UK

Is the UK set to become a radiopharma leader?

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Dr Juliana Maynard, Head of Translational Imaging at Medicines Discovery Catapult. MDC recently announced a partnership with the UK National Nuclear Lab, and Maynard’s… Read More

#Cancer Research #Featured Podcasts #Podcasts

#Drug discovery #Tropical disease #University of Dundee

University of Dundee leads effort to tackle ‘cruel’ disease 

The University of Dundee has revealed plans to develop therapies to tackle a deadly tropical disease.  The £10 million ($13.4 million) project will accelerate research on new therapies for schistosomiasis. The disease is a chronic illness caused by microscopic worms found in contaminated freshwater. Found largely in Africa, South America, and Asia,… Read More

#News

#AI #Antimicrobial resistance (AMR) #Drug discovery #Genomics #India #Oncology

India: Who should we be watching in the drug discovery space?

Diana Turner takes a look at drug discovery in India, a country making the shift from scale to innovation.  While the Indian pharmaceuticals sector has long held a key global position as a centre for generics development and manufacturing, the country is beginning to make a significant name for itself as a… Read More

#Exclusive Content